Skyhawk Therapeutics inks deal with Takeda for neuro disease targets

In a third collaboration with a pharma major within less than a year, US privately-held biotech Skyhawk Therapeutics has entered into a strategic collaboration with Japanese giant Takeda Pharmaceutical (TYO: 4502).

Under the terms of the deal, financial terms of which were not disclosed, Skyhawk will use its SkySTAR technology platform to discover and pre-clinically develop innovative small molecule treatments directed to certain neurological disease targets.

The agreement grants Takeda an exclusive worldwide license to develop and commercialize compounds and products directed to multiple targets while Skyhawk receives an undisclosed upfront payment and is eligible to receive future milestone payments and royalties. As part of the agreement, Takeda will be responsible for clinical development and potential commercialization.